muscle function

Biotech

Chasing Big Pharma rivals, NMD posts data on rare disease drug

NMD thinks its drug may improve health issues that therapies from AstraZeneca, argenx, Johnson & Johnson and UCB are unable to address.
Nick Paul Taylor Oct 11, 2022 6:48am

Aeon hits phase 2 goals in rare disorder

Sep 23, 2022 11:30am

Astellas quietly cuts $450M-plus Cytokinetics R&D pact

May 3, 2021 7:15am

Dyne Therapeutics gunning for $100M IPO weeks after a VC raise

Aug 26, 2020 7:55am

Fulcrum's losmapimod fails muscle wasting interim analysis

Aug 11, 2020 9:06am

Avidity nets $100M to bankroll muscle disorder pipeline

Nov 13, 2019 4:00pm